Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
ClinicalTrials.gov study NCT06198751. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
ClinicalTrials.gov study NCT00629278. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT02990845. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
ClinicalTrials.gov study NCT06125834. IPD Sharing: NO. Countries: 1. Publications: 10.
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
ClinicalTrials.gov study NCT04568902. IPD Sharing: YES. Countries: 1. Publications: 1.
Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)
ClinicalTrials.gov study NCT05735392. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hor
ClinicalTrials.gov study NCT01805271. IPD Sharing: Not stated. Countries: 1. Publications: 3.
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
ClinicalTrials.gov study NCT01109095. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
ClinicalTrials.gov study NCT01669239. IPD Sharing: Not stated. Countries: 1. Publications: 1.
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
ClinicalTrials.gov study NCT06001762. IPD Sharing: YES. Countries: 1. Publications: 0.
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
ClinicalTrials.gov study NCT05880927. IPD Sharing: NO. Countries: 1. Publications: 1.
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
ClinicalTrials.gov study NCT04895761. IPD Sharing: NO. Countries: 1. Publications: 22.
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
ClinicalTrials.gov study NCT01590719. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
ClinicalTrials.gov study NCT03820063. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
ClinicalTrials.gov study NCT00932373. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
ClinicalTrials.gov study NCT00426530. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer
ClinicalTrials.gov study NCT03892655. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
ClinicalTrials.gov study NCT04616560. IPD Sharing: YES. Countries: 1. Publications: 0.
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
ClinicalTrials.gov study NCT05900206. IPD Sharing: NO. Countries: 1. Publications: 1.
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
ClinicalTrials.gov study NCT01564056. IPD Sharing: Not stated. Countries: 2. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.